ACTU: Target konsensus Actuate Therapeutics Inc

Actuate Therapeutics, Inc. (ACTU) adheres to strict ESG standards, minimizing harmful emissions and water consumption during the production of oncology drugs. The asset's market dynamics, shown below, are recorded at 10.27. The business model relies on the complete outsourcing of molecule testing to third-party organizations, while its financial condition is dependent on external investments due to a lack of profitable products and negative cash flow during phase II trials.

ACTU - Target konsensus Actuate Therapeutics, Inc. ing rentang 14.08.2024 - 22.10.2026

Rincian analitis perusahaan Actuate Therapeutics, Inc (ACTU)

Indikator analitis utama Actuate Therapeutics Inc (ACTU):

Rega saham actuatetherapeutics.com|ACTU - Prakiraan konsensus analis|Biji pasar Actuate Therapeutics, Inc

Analisis fundamental perusahaan:actuatetherapeutics.com (ACTU)

Produk asli Actuate Therapeutics, Inc

The average investment bank forecast trend for Actuate Therapeutics, Inc. (ACTU) reflects market expectations regarding the success of oncology drug clinical trials conducted in partnership with global institutions. This indicator synthesizes daily target prices from financial institutions, adjusted for currency fluctuations, allowing investors to identify the business valuation pivot point and determine the optimal entry timing while accounting for the margin of safety.

Perusahaan pesaing

Prakiraan konsensus analis beigene.com (ONC)|Prakiraan konsensus analis HALO (Halozyme)|RVMD - Target konsensus|AAPG: Target konsensus|CG Oncology Therapeutics - Rega prakiraan analis|URGN (UroGen Pharma Ltd.) - Target konsensus|bicara.com (BCAX) - Prakiraan konsensus analis|PSNL (Personalis) - Prakiraan konsensus analis|Target konsensus Erasca Inc (ERAS)|Prakiraan konsensus analis DCTH|Prakiraan konsensus analis Y-mAbs Corp (YMAB)|Bagan rega target Aura Biosciences, Inc. AURA|CADL: Prakiraan gabungan firma investasi|Accuray - Prakiraan konsensus analis|SELLAS Life Sciences (SLS) - Target konsensus|CTOR: Prakiraan konsensus analis|Rata-rata rega prakiraan TuHURA Biosciences (HURA)|Bagan rega target Protara Therapeutics|FATE: Konsensus nilai wajar|Target konsensus WHWK (Aadi Bioscience Inc)|TCRX (tscan.com) - Konsensus nilai wajar|Prakiraan konsensus analis CSBR (Champions Oncology, Inc.)|XBIT - Target konsensus|CVM: Target konsensus|OSTX - Prakiraan konsensus analis|Radiopharm Theranostics Limited (RADX) - Bagan rega target|Artiva Biotherapeutics - Konsensus nilai wajar|ANL (Adlai Nortye Ltd) - Prakiraan konsensus analis|Rata-rata rega prakiraan Veru Corporation VERU|Prakiraan konsensus analis TPST|Prakiraan konsensus analis xiliotx.com (XLO)|Prakiraan konsensus analis RENB (Renovaro)|MURA - Target konsensus|KAPA: Target konsensus|OnKure Therapeutics Inc - Rega prakiraan analis|GDTC (w2.cytomed.sg) - Target konsensus|Curis (CRIS) - Prakiraan konsensus analis|APLM (Apollomics Inc.) - Prakiraan konsensus analis|Prakiraan konsensus analis Tharimmune Inc|Target konsensus ADVB (Advanced Biomed Inc)|Rega prakiraan analis GNPX|Prakiraan konsensus analis CLDI (Calidi Biotherapeutics, Inc.)|Sunshine Biopharma Inc. (SBFM) - Rata-rata rega prakiraan|XBIO: Target konsensus|Konsensus nilai wajar SLRX (Salarius Pharmaceuticals Inc)|PPBT (Purple Biotech Corp) - Target konsensus|AONC: Rega prakiraan analis|BGNE (BeiGene, Ltd.) - Prakiraan konsensus analis|CKPT: Konsensus nilai wajar|Prakiraan konsensus analis ELEV|ICAD - Rata-rata rega prakiraan|Bagan rega target Ikena Oncology IKNA|Konsensus nilai wajar NTBL|Viracta - Prakiraan konsensus analis|MOR - Prakiraan konsensus analis|NAYA Biosciences Inc. (NAYA) - Bagan rega target|Bagan tingkat prakiraan AAPGV (Ascentage Pharma Group International)